240 related articles for article (PubMed ID: 19201101)
1. Use of anti-tumor necrosis factor agents: a possible therapy for vitiligo.
Lv Y; Li Q; Wang L; Gao T
Med Hypotheses; 2009 May; 72(5):546-7. PubMed ID: 19201101
[TBL] [Abstract][Full Text] [Related]
2. Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab.
Simón JA; Burgos-Vargas R
Dermatology; 2008; 216(3):234-5. PubMed ID: 18182816
[TBL] [Abstract][Full Text] [Related]
3. Treatment of generalized vitiligo with anti-TNF-α Agents.
Alghamdi KM; Khurrum H; Taieb A; Ezzedine K
J Drugs Dermatol; 2012 Apr; 11(4):534-9. PubMed ID: 22453596
[TBL] [Abstract][Full Text] [Related]
4. Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts.
Sweiss NJ; Curran J; Baughman RP
Clin Dermatol; 2007; 25(3):341-6. PubMed ID: 17560312
[TBL] [Abstract][Full Text] [Related]
5. Endothelin-1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF-α-inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: a proposed action mechanism for combination therapy of phototherapy and topical tacrolimus in vitiligo treatment.
Lee KY; Jeon SY; Hong JW; Choi KW; Lee CY; Choi SJ; Kim JH; Song KH; Kim KH
J Eur Acad Dermatol Venereol; 2013 May; 27(5):609-16. PubMed ID: 22404745
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of infliximab in active SLE: a pilot study.
Uppal SS; Hayat SJ; Raghupathy R
Lupus; 2009 Jul; 18(8):690-7. PubMed ID: 19502264
[TBL] [Abstract][Full Text] [Related]
7. Improvement of idiopathic pyoderma gangrenosum during treatment with anti-tumor necrosis factor alfa monoclonal antibody.
Dini V; Romanelli M; Bertone M; Talarico S; Bombardieri S; Barachini P
Int J Low Extrem Wounds; 2007 Jun; 6(2):108-13. PubMed ID: 17558009
[TBL] [Abstract][Full Text] [Related]
8. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
Fiorino G; Allez M; Malesci A; Danese S
Aliment Pharmacol Ther; 2009 May; 29(9):921-7. PubMed ID: 19210297
[TBL] [Abstract][Full Text] [Related]
9. Potential target of infliximab in autoimmune and inflammatory diseases.
Atzeni F; Doria A; Carrabba M; Turiel M; Sarzi-Puttini P
Autoimmun Rev; 2007 Sep; 6(8):529-36. PubMed ID: 17854744
[TBL] [Abstract][Full Text] [Related]
10. Autoimmunity as an aetiological factor in vitiligo.
Rezaei N; Gavalas NG; Weetman AP; Kemp EH
J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):865-76. PubMed ID: 17658994
[TBL] [Abstract][Full Text] [Related]
11. Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions.
Cordiali-Fei P; Trento E; D'Agosto G; Bordignon V; Mussi A; Ardigó M; Mastroianni A; Vento A; Solivetti F; Berardesca E; Ensoli F
Ann N Y Acad Sci; 2007 Sep; 1110():578-89. PubMed ID: 17911474
[TBL] [Abstract][Full Text] [Related]
12. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes.
Stasi R; Amadori S
Br J Haematol; 2002 Feb; 116(2):334-7. PubMed ID: 11841434
[TBL] [Abstract][Full Text] [Related]
13. The tumor necrosis factor-{alpha}-blocking agent infliximab inhibits interleukin 1beta (IL-1beta) and IL-6 gene expression in human osteoblastic cells.
Musacchio E; Valvason C; Botsios C; Ostuni F; Furlan A; Ramonda R; Modesti V; Sartori L; Punzi L
J Rheumatol; 2009 Aug; 36(8):1575-9. PubMed ID: 19567627
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.
Danese S
Dig Liver Dis; 2008 Jul; 40 Suppl 2():S225-8. PubMed ID: 18598993
[TBL] [Abstract][Full Text] [Related]
15. Over-expression of tumor necrosis factor-α in vitiligo lesions after narrow-band UVB therapy: an immunohistochemical study.
Attwa E; Gamil H; Assaf M; Ghonemy S
Arch Dermatol Res; 2012 Dec; 304(10):823-30. PubMed ID: 22832941
[TBL] [Abstract][Full Text] [Related]
16. Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature.
Moll C; Hernández MV; Cañete JD; Gómez-Puerta JA; Soriano A; Collado A; Sanmartí R
Semin Arthritis Rheum; 2008 Apr; 37(5):299-306. PubMed ID: 17976692
[TBL] [Abstract][Full Text] [Related]
17. Refractory Takayasu arteritis successfully treated with infliximab.
Maffei S; Di Renzo M; Santoro S; Puccetti L; Pasqui AL
Eur Rev Med Pharmacol Sci; 2009; 13(1):63-5. PubMed ID: 19364087
[TBL] [Abstract][Full Text] [Related]
18. Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo.
Webb KC; Tung R; Winterfield LS; Gottlieb AB; Eby JM; Henning SW; Le Poole IC
Br J Dermatol; 2015 Sep; 173(3):641-50. PubMed ID: 26149498
[TBL] [Abstract][Full Text] [Related]
19. Basic fibroblast growth factor and tumour necrosis factor alpha in vitiligo and other hypopigmented disorders: suggestive possible therapeutic targets.
Seif El Nasr H; Shaker OG; Fawzi MM; El-Hanafi G
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):103-8. PubMed ID: 22151832
[TBL] [Abstract][Full Text] [Related]
20. The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model.
Larmonier N; Cathelin D; Larmonier C; Nicolas A; Merino D; Janikashvili N; Audia S; Bateman A; Thompson J; Kottke T; Hartung T; Katsanis E; Vile R; Bonnotte B
Exp Cell Res; 2007 Jul; 313(11):2345-55. PubMed ID: 17466973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
